Generated October 20, 2026 at 4:36 PM ET
· Covers October 20 trading day
· 10 of 174 ready 8-Ks selected
· AI-assisted overview
The day's most material 8-K filings were dominated by M&A: Salesforce agreed to acquire Braze for $47.50 per share in cash, Prudential Financial agreed to sell its Brazil and Mexico units to CNP Assurances for about $4.025 billion, and Myriad Genetics agreed to sell its prenatal health testing business to Labcorp for $210 million. Earnings filings included Annaly Capital Management, which reported a Q3 GAAP loss of $1.36 per share alongside a decline in book value to $17.86 from $20.15, while Neptune Insurance and Peoples Bancorp reported higher revenue and net income. Rapport Therapeutics disclosed positive Phase 2 results for RAP-219 in bipolar mania, and Filana Therapeutics noted a Fifth Circuit ruling vacating class certification in a securities suit. Two Nasdaq compliance items rounded out the list: XWELL received a minimum bid price notice with an April 5, 2027 cure deadline, and Wellgistics Health reported that DataMeds AI regained stockholders' equity compliance.
NLY
ANNALY CAPITAL MANAGEMENT INC
earnings
negative
materiality 0.80
October 20, 2026, 4:15 PM ET
Annaly Q3 2026 GAAP loss of $1.36/share; EAD $0.80, book value falls to $17.86 from $20.15
- GAAP net loss of $(1.36) per average common share versus $1.06 income in Q2 2026; annualized GAAP ROE of -24.35% and economic return of -7.6%.
- Earnings available for distribution of $0.80 per share exceeded the $0.75 common dividend; annualized EAD ROE 15.86%, net interest margin 1.54% (1.69% excluding PAA).
- Book value per common share fell to $17.86 from $20.15 at June 30 and $19.25 a year earlier; GAAP leverage rose to 8.0x from 7.4x, economic leverage to 5.9x from 5.6x.
M&A
positive
materiality 0.90
October 20, 2026, 9:11 AM ET
Salesforce to acquire Braze for $47.50 per share in cash; Braze board unanimously approves
- Salesforce's Banff Acquisition Sub will merge into Braze; each Braze Class A share converts into $47.50 in cash at closing.
- Braze must pay Parent $191,390,000 if it accepts a superior proposal or its board withdraws support; Parent pays Braze $300,000,000 if regulators permanently block the deal.
- Closing conditions include a majority vote of Braze Class A holders, HSR clearance and other antitrust/foreign-investment approvals; outside date Oct 19, 2027, extendable twice by 90 days.
PRU
PRUDENTIAL FINANCIAL INC
M&A
positive
materiality 0.80
October 20, 2026, 7:31 AM ET
Prudential Financial to sell Brazil and Mexico units to CNP Assurances for $4.025B cash
- Aggregate purchase price of approximately $4.025 billion in cash, subject to closing adjustments; deal expected to close in H2 2027 pending regulatory approvals.
- Sells 100% of equity in Prudential do Brasil Seguros S.A. and Prudential Seguros Mexico, S.A. de C.V. to CNP Seguradora and CNP Assurances Holding.
- Follows sales of stakes in PT PFI Mega Life (Indonesia), Alexforbes (South Africa) and ICEA LION (Kenya), which closed October 13, as Prudential exits emerging markets.
M&A
positive
materiality 0.90
October 20, 2026, 8:36 AM ET
Myriad Genetics to sell prenatal health testing business to Labcorp for $210 million cash
- Myriad Genetics agreed to sell its Prenatal Health testing business, including Prequel, Foresight, SneakPeek and FirstGene, to Labcorp for $210 million cash plus closing inventory value.
- Labcorp expects the acquisition to add about $160 million in revenue in year one, be slightly accretive to adjusted earnings in year one, and reach diagnostics segment margins by end of year two.
- The deal is subject to HSR and state health care approvals and is expected to close by early 2027; either party may terminate if not closed by Feb. 19, 2027, with extension to Oct. 19, 2027.
regulatory
negative
materiality 0.60
October 20, 2026, 8:00 AM ET
XWELL gets Nasdaq $1.00 minimum bid price notice; deadline April 5, 2027 to regain compliance
- Nasdaq staff letter dated Oct 7, 2026: closing bid price below $1.00 for 30 consecutive business days from Aug 25 through Oct 6, 2026.
- 180-calendar-day compliance period runs until April 5, 2027; requires a closing bid of at least $1.00 for a minimum of 10 consecutive business days.
- Any reverse stock split used to cure the deficiency must be completed at least 10 business days before April 5, 2027.
WGRX
Wellgistics Health, Inc.
regulatory
positive
materiality 0.55
October 20, 2026, 9:24 AM ET
DataMeds AI regains Nasdaq $2.5M stockholders' equity compliance after April delisting notice
- Nasdaq Staff notice dated Oct. 19, 2026 confirms DataMeds AI is back in compliance with Listing Rule 5550(b)(1), which requires $2.5M minimum stockholders' equity.
- The April 13, 2026 delisting notice cited stockholders' equity of $(12,447,801) at Dec. 31, 2025 and a separate failure to meet the $1.00 minimum bid price.
- Bid-price compliance was regained June 9, 2026; equity cure was evidenced in Form 8-K filings on Oct. 13 and Oct. 16, 2026 showing equity above $2.5M.
NP
Neptune Insurance Holdings Inc.
earnings
positive
materiality 0.85
October 20, 2026, 4:15 PM ET
Neptune Insurance Q3 revenue up 34% to $59.6M, net income $17.3M; CFO Steiner to exit after 2026 10-K
- Q3 revenue $59.6M vs $44.4M a year ago (+34%); net income $17.3M (+50%) at a 29% margin; diluted EPS $0.12, adjusted diluted EPS $0.17.
- Adjusted EBITDA $36.8M (+38%) at a 61.7% margin; adjusted net income $24.3M (+52%); written premium $132.7M (+31%) on record new business sales.
- Raises FY2026 revenue outlook to $204M with Adjusted EBITDA margin above 61%; sets initial 2027 guidance of $238M revenue at a 61% margin.
FLNA
FILANA THERAPEUTICS, INC.
litigation
positive
materiality 0.55
October 20, 2026, 8:17 AM ET
Fifth Circuit vacates class certification in Filana securities suit, sends case back to Texas district court
- Fifth Circuit on Oct 16, 2026 vacated the Western District of Texas order granting class certification against Filana Therapeutics and named officers and employees.
- Class had covered all purchasers of Filana securities from September 14, 2020 through October 12, 2023; certification proceedings now proceed on remand.
- Appeals court held the district court misapplied the legal standard, failing to weigh market-inefficiency evidence and improperly rejecting the meme-stock argument.
RAPP
Rapport Therapeutics, Inc.
other material
positive
materiality 0.80
October 20, 2026, 6:05 AM ET
Rapport's RAP-219 hits Phase 2 primary endpoint in bipolar mania (3.1-pt YMRS gain, p=0.045)
- Phase 2 met primary endpoint: 3.1-point placebo-adjusted YMRS improvement at Week 3 (p=0.045); 15.4-point mean reduction from baseline vs 12.3 on placebo.
- Secondary CGI-BP mania severity improved 0.4 points vs placebo (p=0.024); all 11 YMRS items improved, with 4 reaching nominal significance.
- 253 adults with bipolar I mania enrolled (126 on RAP-219 0.75 mg, 127 placebo); all TEAEs mild or moderate, no SAEs; 3.2% vs 0.8% discontinued for TEAE.
earnings
positive
materiality 0.70
October 20, 2026, 6:09 AM ET
Peoples Bancorp Q3 2026 net income $32.6M, EPS $0.91 vs $0.83; NIM 4.31%; dividend $0.42
- Net income $32.6M and diluted EPS $0.91, up from $28.0M/$0.78 in Q2 2026 and $29.5M/$0.83 in Q3 2025; non-core items cut EPS by $0.13.
- Net interest income $93.8M, up $1.1M QoQ and 3% YoY; NIM 4.31% vs 4.23% linked quarter and up 15 bps YoY on higher loan and investment yields.
- Provision for credit losses fell to $3.6M from $4.7M QoQ and $7.3M a year ago; period-end loans and core deposits each rose $19.2M QoQ.